ANUA Stock Overview
A late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
XORTX Therapeutics Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$2.00 |
52 Week High | CA$7.65 |
52 Week Low | CA$0.30 |
Beta | -0.082 |
1 Month Change | -34.85% |
3 Month Change | -1.48% |
1 Year Change | -66.88% |
3 Year Change | -83.10% |
5 Year Change | -82.63% |
Change since IPO | -96.09% |
Recent News & Updates
Recent updates
Shareholder Returns
ANUA | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -16.7% | 6.1% | 1.6% |
1Y | -66.9% | -17.5% | 7.3% |
Return vs Industry: ANUA underperformed the German Pharmaceuticals industry which returned -21.6% over the past year.
Return vs Market: ANUA underperformed the German Market which returned 6.5% over the past year.
Price Volatility
ANUA volatility | |
---|---|
ANUA Average Weekly Movement | 26.1% |
Pharmaceuticals Industry Average Movement | 7.0% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 10.6% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: ANUA's share price has been volatile over the past 3 months.
Volatility Over Time: ANUA's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 3 | Allen Davidoff | www.xortx.com |
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.
XORTX Therapeutics Inc. Fundamentals Summary
ANUA fundamental statistics | |
---|---|
Market cap | €6.50m |
Earnings (TTM) | -€1.98m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.3x
P/E RatioIs ANUA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ANUA income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$2.16m |
Earnings | -US$2.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.74 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did ANUA perform over the long term?
See historical performance and comparison